Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Policy / Regulatory

GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023

Fineline Cube Aug 7, 2023

The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking...

Company Medical Device

Venus Medtech Receives FDA IDE Approval for VenusP-Valve, a Milestone for Chinese Heart Valve Technology

Fineline Cube Aug 7, 2023

Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced obtaining Investigational Device Exemption (IDE) approval from...

Company Medical Device

MicroPort CardioFlow Announces Positive Results for Transcatheter Mitral Valve Replacement System

Fineline Cube Aug 7, 2023

China-based MicroPort Scientific Corp’s spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced positive...

Company Deals

Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation

Fineline Cube Aug 7, 2023

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and...

Company Deals

Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China

Fineline Cube Aug 7, 2023

China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing...

Company

Gilead Sciences Inc. Reports 5% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 4, 2023

US-based pharmaceutical major Gilead Sciences Inc., (NASDAQ: GILD) has released its financial results for the...

Company Legal / IP

Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 4, 2023

US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second...

Company Legal / IP

GSK Files Patent Infringement Lawsuit Against Pfizer’s RSV Vaccine Abrysvo

Fineline Cube Aug 4, 2023

UK pharmaceutical giant GlaxoSmithKline (NYSE: GSK) has taken US-based Pfizer Inc., (NYSE: PFE) to court,...

Company Deals

Novartis AG and Ionis Pharmaceuticals Renew Collaboration on Lp(a)-Driven CVD Drug

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has returned to US-based Ionis Pharmaceuticals Inc., (NASDAQ:...

Company Drug

Grand Pharmaceutical Group Gets NMPA Approval for Generic Eplerenone for Hypertension

Fineline Cube Aug 4, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Company Deals

Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal

Fineline Cube Aug 4, 2023

China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive...

Company Medical Device

DaVinci Single Port System Launches in Hainan with Successful Surgeries

Fineline Cube Aug 4, 2023

The DaVinci Single Port robot-assisted surgical system technology has been successfully implemented in Boao, Hainan...

Policy / Regulatory

Shanghai’s SMPA Reduces Ceiling Price for Non-Winning Bids in Artificial Joint VBP Tender

Fineline Cube Aug 4, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification regarding an artificial joint volume-based...

Company Deals

Kunshan Yiyuan Medical Technology Secures Over RMB 100 Million in Series B Financing

Fineline Cube Aug 4, 2023

Kunshan Yiyuan Medical Technology Co., Ltd (Medical Source), a company in China that specializes in...

Company Deals

HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max

Fineline Cube Aug 4, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm...

Company

Novartis China’s Business Growth Lead Zhu Jiakang Departs for Personal Reasons

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has seen the departure of Zhu Jiakang, who led...

Company

BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth

Fineline Cube Aug 3, 2023

China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report...

Legal / IP Policy / Regulatory

National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector

Fineline Cube Aug 3, 2023

An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July...

Company Medical Device

Our United Corporation’s Linear Accelerator Approved as Innovative Medical Device by NMPA

Fineline Cube Aug 3, 2023

Xi’an-based Our United Corporation has announced that its medical electronic linear accelerator has been approved...

Company Drug

CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101

Fineline Cube Aug 3, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...

Posts pagination

1 … 545 546 547 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.